Aadi Bioscience

A series of dice with a bag on them illustrating cost cuts

Pharma

Aadi lays off 80% of R&D workforce as Fyarro heads to ph. 2 fail

Aadi Bioscience’s Fyarro is on track to fail a phase 2 solid tumor trial, leading the biotech to halt the study and lay off 80% of its R&D workforce.

James Waldron Aug 21, 2024 4:51am

Fyarro Aadi Bioscience

Aadi's cancer nod propels company into the commercial realm

Nov 23, 2021 11:10am